The startup has emerged from stealth with $77.6m from backers including Boehringer Ingelheim to advance four potential cancer treatments into the clinic.

T-Knife, a Germany-based developer of T-cell receptor therapeutics, has received €66m ($77.6m) in series A funding from investors including Boehringer Ingelheim Venture Fund (BIVF), the investment arm of pharmaceutical firm Boehringer Ingelheim.

The round was co-led by Versant Ventures and RA Capital Management and was also backed by Andera Partners.

Founded in 2018, T-Knife is working on cancer drugs based on T-cell receptors (TCRs) made using mice that have been reengineered to contain biological material that resembles the location of…